[1]黄国初,黄古叶,顾桥,等.健肝颗粒Ⅱ方联合恩替卡韦治疗乙肝e抗原阳性慢性乙型病毒性肝炎150例临床观察[J].甘肃中医药大学学报,2018,35(01):51-54.[doi:10.16841/j.issn1003-8450.2018.01.14]
 HUANG Guochu,HUANG Guye,GU Qiao,et al.Effect of Jiangan Keli Ⅱ and entecavir in treating 150 cases of HBeAg positive chronic hepatitis B[J].Journal of Gansu University of Chinese Medicine,2018,35(01):51-54.[doi:10.16841/j.issn1003-8450.2018.01.14]
点击复制

健肝颗粒Ⅱ方联合恩替卡韦治疗乙肝e抗原阳性慢性乙型病毒性肝炎150例临床观察()
分享到:

《甘肃中医药大学学报》[ISSN:1003-8450/CN:62-1062/R]

卷:
35卷
期数:
2018年01期
页码:
51-54
栏目:
临床研究与报道
出版日期:
2018-02-25

文章信息/Info

Title:
Effect of Jiangan Keli Ⅱ and entecavir in treating 150 cases of HBeAg positive chronic hepatitis B
作者:
黄国初1 黄古叶1 顾桥2 龙艺方2 潘攀2
1. 广西中医药大学第一附属医院肝病二区, 广西 南宁 530023;
2. 广西中医药大学第一临床医学院, 广西 南宁 530023
Author(s):
HUANG Guochu1 HUANG Guye1 GU Qiao2 LONG Yifang2 PAN Pan2
1. The Second Hepatology Department, the First Affiliated Hospital to Guangxi University of Chinese Medicine, Nanning, Guangxi, 530023, China;
2. The First Clinical Medicine College, Guangxi University of Chinese Medicine, Nanning, Guangxi, 530023, China
关键词:
乙肝e抗原阳性慢性乙型病毒性肝炎健肝颗粒Ⅱ方恩替卡韦临床观察
Keywords:
HBeAg positive chronic hepatitis BJiangan Keli Ⅱentecavirclinical observation
分类号:
R259.126
DOI:
10.16841/j.issn1003-8450.2018.01.14
摘要:
目的 观察健肝颗粒Ⅱ方联合恩替卡韦治疗乙肝e抗原(HBeAg)阳性慢性乙型病毒性肝炎(CHB)的临床疗效。方法 将300例HBeAg阳性CHB患者随机分为对照组和治疗组,各150例。对照组给予恩替卡韦治疗,治疗组在对照组治疗方法的基础上给予健肝颗粒Ⅱ方。治疗52周后比较2组治疗前后患者外周血丙氨酸氨基转移酶(ALT)、血清乙肝病毒脱氧核糖核酸(HBV-DNA)载量、HBeAg及乙肝e抗体(HBeAb)血清学转换情况。结果 与对照组比较,治疗组HBeAg转阴率及HBeAb转阳率均显著升高,差异有统计学意义(P<0.05)。与同组治疗前比较,2组外周血ALT及血清HBV-DNA载量显著降低,差异均有统计学意义(P<0.01),且治疗组外周血ALT降低幅度明显大于对照组(P<0.05)。对照组ALT复常率为65.3%,治疗组为78.0%,2组比较差异有统计学意义(P<0.01);对照组血清HBV-DNA载量低于检测限比率为62.7%,治疗组为74.7%,2组比较差异有统计学意义(P<0.05)。结论 健肝颗粒Ⅱ方联合恩替卡韦治疗HBeAg阳性CHB疗效显著,可升高患者的HBeAg转阴率、HBeAb转阳率、ALT复常率及血清HBV-DNA载量低于检测限比率,其疗效优于单用恩替卡韦。
Abstract:
Objective To observe the clinical effect of Jiangan Keli Ⅱ combined with entecavir in treating HBeAg positive chronic hepatitis B (HBeAg positive CHB).Methods 300 cases of HBeAg positive CHB were randomized into control group and treatment group,150 cases in each. The control group was treated with entecavir;the treatment group was intervened with Jiangan Keli Ⅱcombined with entecavir. Treating for 52 weeks,peripheral blood ALT,load of HBV-DNA,serological conversion of HBeAg and HBeAb were recorded and tested.Results Compared with control group,negative conversion ratio of HBeAg and positive conversion ratio of HBeAb in treatment group increased obviously,the difference was significant (P<0.05). After treatment,peripheral blood ALT,load of HBV-DNA in both groups decreased notably,the difference was significant (P<0.01),while peripheral blood ALT dropped more in treatment group,there were significant differences (P<0.05). Recovery rates of ALT in treatment group and control group were 78.0% and 65. 3% respectively,the difference was significant (P<0.01). HBV-DNA ratio to the low limit of detection in treatment group was 74.7%,while that in control group was 62.7%,there was a statistic difference (P<0.05).Conclusion The joint therapy is effective in promoting negative conversion ratio of HBeAg,positive conversion ratio of HBeAb,recovery rate of ALT and HBV-DNA ratio to the low limit of detection. It is better than by using entecavir alone.

参考文献/References:

[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].肝脏,2011,16(1):2-16.
[2] Naghavi M,Wang H D,Lozano R,et al.Global,regional and national age-sex specific all-cause and cause-specific morta-lity for 240 causes of death,1990 to 2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet,2015,385(9963):117-171.
[3] Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.
[4] Ott J J,Stevens G A,Groeger J,et al.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity[J].Vaccine,2012,30(12):2212-2219.
[5] 黄古叶.健肝散治疗慢性乙型肝炎肝纤维化35例[J].中国中西医结合消化杂志,2005,13(1):53-54.
[6] 黄古叶,胡振斌,毛德文,等.健肝散抗慢性乙型肝炎肝纤维化的作用及其机制研究[J].现代中医药,2007,27(6):11-13.
[7] 黄古叶,龙富立,胡振斌,等.健肝散联合恩替卡韦片对乙型肝炎早期肝硬化血清纤维化指标的影响[J].新中医,2009,41(11):30-31.
[8] 黄古叶,龙富立,毛德文,等.健肝颗粒对大鼠肝纤维化组织中TGF-β1和NF-kB mRNA表达的影响[J].陕西中医学院学报,2012,35(5):85-87.
[9] 黄古叶,龙富立,毛德文,等.健肝颗粒对大鼠肝纤维化脂质过氧化物生成的影响[J].中华中医药学刊,2012,30(10):2232-2234.

备注/Memo

备注/Memo:
收稿日期:2017-5-5。
基金项目:2013年广西卫生适宜技术研究与开发项目(S201307-02)。
作者简介:黄国初(1987-),男,住院医师,医学硕士。研究方向:中西医结合防治肝病的研究。
通信作者:黄古叶(1969-),男,教授,主任医师,硕士生导师,医学学士。研究方向:中西医结合防治肝病的基础与临床研究。E-mail:huangguye@163.com
更新日期/Last Update: 1900-01-01